Asia Pacific Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Country: Trend Forecast and Growth Opportunity

  • Product Code:
    RP-ID-10352323
  • Published Date:
    7 Jan 2022
  • Region:
    Regional
  • Pages:
    108
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Pub-ID-26

Impact Analysis on the Growth of Market

Inflation and Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.

..

..

The Research Report is Updated with 2021 Base Year, 2022 Estimated year and Forecast till 2031 with Market Insights.


With the dip in global production, the GDP has contracted in 2020 and impacted the market across the world. Upon placing a Sample Request, you will receive an updated report with 2021 as base year, 2022 as estimated year and forecast to 2031. This will have market drivers, recovery rate in the market, insights and competitive analysis.



Market Overview:

Translate Report

Asia Pacific monoclonal antibodies market will grow by 12.8% annually with a total addressable market cap of $414 billion over 2021-2030 owing to the increasing incidences of new cancer cases and other diseases, growth in geriatric population, increasing pharmaceutical R&D spending, upsurge in healthcare expenditure, and the rising adoption of cost-efficient biosimilar monoclonal antibodies.
Highlighted with 31 tables and 51 figures, this 108-page report “Asia Pacific Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific monoclonal antibodies market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific monoclonal antibodies market in every aspect of the classification from perspectives of Source, Category, Production Type, Application, End User, and Country.

Based on Source, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Human
• Humanized
• Chimeric
• Murine

Based on Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Branded mAbs
• Biosimilar mAbs

Based on Production Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• In Vitro Production
• In Vivo Production

Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Cancer
o Breast Cancer
o Colorectal Cancer
o Lung Cancer
o Ovarian Cancer
o Other Cancer Types
• Autoimmune Diseases
• Inflammatory Diseases
• Infectious Diseases
• Other Applications

By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Hospitals
• Research Institutes
• Other End Users

Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of key national markets by Source, Application, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
AbbVie, Inc.
Amgen Inc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Co., Inc.
Mylan N.V
Norvatis AG
Pfizer
Sanofi S.A.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)



.

1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the Market 22
2.2 Major Growth Drivers 24
2.3 Market Restraints and Challenges 29
2.4 Emerging Opportunities and Market Trends 32
2.5 Porter’s Fiver Forces Analysis 36
3 Segmentation of Asia Pacific Market by Source 40
3.1 Market Overview by Source 40
3.2 Human 42
3.3 Humanized 43
3.4 Chimeric 44
3.5 Murine 45
4 Segmentation of Asia Pacific Market by Category 46
4.1 Market Overview by Category 46
4.2 Branded mAbs 48
4.3 Biosimilar mAbs 49
5 Segmentation of Asia Pacific Market by Production Type 50
5.1 Market Overview by Production Type 50
5.2 In Vitro Production 52
5.3 In Vivo Production 53
6 Segmentation of Asia Pacific Market by Application 54
6.1 Market Overview by Application 54
6.2 Cancer 56
6.2.1 Breast Cancer 58
6.2.2 Colorectal Cancer 59
6.2.3 Lung Cancer 60
6.2.4 Ovarian Cancer 61
6.2.5 Other Cancer Types 62
6.3 Autoimmune Diseases 63
6.4 Inflammatory Diseases 64
6.5 Infectious Diseases 65
6.6 Other Applications 66
7 Segmentation of Asia Pacific Market by End User 67
7.1 Market Overview by End User 67
7.2 Hospitals 69
7.3 Research Institutes 70
7.4 Other End Users 71
8 Asia-Pacific Market 2019-2030 by Country 72
8.1 Overview of Asia-Pacific Market 72
8.2 Japan 75
8.3 China 78
8.4 Australia 80
8.5 India 82
8.6 South Korea 84
8.7 Rest of APAC Region 86
9 Competitive Landscape 88
9.1 Overview of Key Vendors 88
9.2 New Product Launch, Partnership, Investment, and M&A 91
9.3 Company Profiles 92
Abbott Laboratories 92
AbbVie, Inc. 94
Amgen Inc. 95
AstraZeneca plc 96
Bayer AG 97
Bristol-Myers Squibb Company 98
Eli Lilly 99
F. Hoffmann-La Roche Ltd. 100
GlaxoSmithKline Plc 101
Johnson & Johnson 102
Merck & Co., Inc. 103
Mylan N.V 104
Norvatis AG 105
Pfizer 106
Sanofi S.A. 107
RELATED REPORTS 108

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
AbbVie, Inc.
Amgen Inc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Co., Inc.
Mylan N.V
Norvatis AG
Pfizer
Sanofi S.A.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports

-->